NIFTY
15.15  0.15%
 10298.75
S&P BSE SENSEX
17.10  0.05%
 33359.9
Cadila Healthcare Ltd.
NSE : CADILAHC BSE : 532321 ISIN code : INE010B01027
on 20-Nov-2017
NSE
-1.4    -0.31%
Rs. 445.55
 
Days Low
Rs. 443.35
Days High
Rs. 453.7

Open Rs. 450.55
 
52 week Low
Rs. 329.95
52 week High
Rs.558
 
 
Bid :                 0.00 (0)
Offer :        446.30 (269)
BSE
Rs.446.30
-0.05    -0.01%
on 20-Nov-2017
BSE
-0.05    -0.01%
Rs. 446.30
 
Days Low
Rs. 443.1
Days High
Rs. 453.95

Open Rs. 451.3
 
52 week Low
Rs. 328.8
52 week High
Rs.560
 
 
Bid :                 0.00 (0)
Offer :        446.30 (269)
NSE
Rs.445.55
-1.4    -0.31%
 
 
Last Price (Rs.)  446.30 Value  34309264.00
Net Change (Rs.)  -0.05 Best Buy  0.00
Volume  76325 Best Sell  446.30
Prev.Close (Rs.)  446.35 Best Quantity  0
Open (Rs.)  450.55 Sell Quantity  269
High (Rs.)  453.70 52-Week High (Rs.)  558.00
Low (Rs.)  443.35 52-Week Low (Rs.)  329.95
Face Value (Rs.)  1 Market Cap.(Rs/ Mn)  456896.32
 
BSE
You need to upgrade your Flash Player
 
Financial (Rs .in Million)
Balance Sheet
Share Capital1024.00 1024.00 1024.00 
Share Capital1024.00 1024.00 1024.00 
Share Capital1024.00 1024.00 1024.00 
Share Capital1024.00 1024.00 1024.00 
Share Capital1024.00 1024.00 1024.00 
Currents Investments0.00 1009.00 4583.00 
More> 
 
Top 5 PeerCompanies * (Rs .in Million)
Company NameLTP* M.CapBVP/EDiv.Yield
Sun Pharma Inds. 516.45 1239123 81.15 0.00 0.68
Cipla 602.60 484986 167.17 49.73 0.33
Piramal Enterprises 2610.90 450545 807.03 58.00 0.80
Aurobindo Pharma 706.65 414014 160.53 24.26 0.35
Dr. Reddys Lab 2277.30 377775 682.01 27.28 0.88
 
Mutual Funds Holdings
 
Quarterly Result
(Rs .in millions)Sep 2017Jun 2017Mar 2017
Net Sales17383.0010554.008285.00
Operating Profit7174.002504.004693.00
PBDT6934.002385.004693.00
Net Profit4498.00914.004714.00
More> 
 
Company News
11/20/2017 12:00:00 AM
L&T, Strides Shasun and Biocon to see some action today
11/20/2017 12:00:00 AM
Cadila Healthcare moves up on getting USFDA nod for Ethacrynate Sodium...
11/20/2017 12:00:00 AM
Zydus’ oral anemia developmental candidate ‘ZYAN1’ named as Desidustat...
More>
 
Ratios
   Earnings Per Share (Rs)6.46 
   Book NAV/Share(Rs)64.63 
   PAT Margin (%)20.21 
   Asset Turnover(x)0.30 
   PER(x)68.57 
   Yield(%)0.72 
   EV/Core EBITDA(x)52.51 
   M Cap / Sales14.05 
   Net Sales Growth(%)-54.06 
   PAT Growth(%)-67.51 
   Total Debt/Equity(x)0.44 
   Current Ratio(x)0.71 
   Quick Ratio(x)0.40 
   Total Debt/Mcap(x)0.06 
More>